Lupin launches Meloxicam Capsules

Lupin Limited (Lupin), global pharmaceutical company, announced today the launch of Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the United States Food and Drug Administration.

Meloxicam Capsules, 5 mg and 10 mg, is the generic equivalent of Vivlodex® Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc., and indicated for management of osteoarthritis (OA) pain.

Meloxicam Capsules (RLD: Vivlodex®) had an annual sales of approximately USD 11 million in the U.S. (IQVIA MAT October 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.978 as compared to the previous close of Rs. 963. The total number of shares traded during the day was 89580 in over 2780 trades.

The stock hit an intraday high of Rs. 981.6 and intraday low of 962. The net turnover during the day was Rs. 87165178.

Source : Equity Bulls

Keywords